Glioblastoma

Glioblastoma is the most aggressive primary brain tumour in adults.

Standard treatment still leaves median survival in the range of roughly 14 to 16 months.

The blood-brain barrier, extreme intratumoural heterogeneity, and fast treatment resistance make glioblastoma one of the hardest targets in oncology.

Urolithin A has a meaningful and growing preclinical evidence base in glioblastoma.

Several groups have studied it across multiple glioblastoma cell lines and at least two in vivo models.

One reason it stands out in this setting is simple but important.

It crosses the blood-brain barrier.

There is no clinical glioblastoma trial evidence yet.

Everything below is preclinical unless clearly stated otherwise.

Blood-brain-barrier penetration

Blood-brain-barrier penetration is a real threshold issue in brain-tumour work.

Many compounds never clear it.

Urolithin A does.

Several lines of evidence support this:

• pharmacokinetic and tissue-distribution work has detected Urolithin A in brain tissue after systemic administration

• animal CNS-injury work showed reduced blood-brain-barrier leakage, preserved tight-junction proteins, and reduced cerebral oedema after Urolithin A treatment

• AACR-presented glioblastoma work specifically cited blood-brain-barrier penetration as one reason the compound was prioritised for study

That does not prove clinical efficacy in glioblastoma.

It does remove one of the biggest early barriers that rule out many other compounds.

Antiproliferative activity across glioblastoma cell lines

Urolithin A has been tested across at least three genetically different glioblastoma lines, including U87, U251, and U373.

The antiproliferative signal appears consistent.

Key findings include:

• reduced cell viability in a dose-dependent and time-dependent way

• inhibition of colony formation

• lower clonogenic survival

• activity across lines with different PTEN, EGFR, and p53 backgrounds

That last point matters.

It suggests the effect is not confined to one narrow molecular subtype.

Cell-cycle arrest, apoptosis, and EMT inhibition

Cell cycle and apoptosis

In U251 cells, Urolithin A produced G2/M arrest, higher pro-apoptotic signalling, and reduced colony formation over time.

This supports both growth arrest and commitment toward apoptosis rather than simple nonspecific toxicity.

EMT inhibition

Glioblastoma invasion is one of the main reasons local control is so difficult.

Urolithin A has been shown to reduce EMT-linked behaviour in glioblastoma models, with lower migration and invasion in both migration and invasion assays.

That makes the compound relevant not only to proliferation but also to infiltrative behaviour.

Sirt1-FOXO1 axis — the strongest mechanistic pathway in glioblastoma

The most detailed glioblastoma mechanism paper identified the Sirt1-FOXO1 axis, acting through ERK and AKT signalling, as the core pathway behind Urolithin A's anti-glioblastoma effects.

This is one of the strongest mechanistic parts of the entire glioblastoma story.

Sirt1 is a NAD-dependent deacetylase with tumour-suppressive roles in some settings.

FOXO1 is a transcription factor linked to cell-cycle arrest, apoptosis, and reduced invasion.

In glioblastoma, suppression of this axis may help support uncontrolled growth.

Urolithin A increased both Sirt1 and FOXO1 expression.

More importantly, this was not just a correlation finding.

Knockdown and overexpression experiments showed that when Sirt1 was suppressed, Urolithin A lost much of its inhibitory effect.

When Sirt1 function was restored, the inhibitory effect returned.

That makes Sirt1 a functional requirement in this model, not just an associated marker.

The in vivo xenograft work supported the same mechanism.

Tumours from Urolithin-A-treated mice were smaller and showed higher Sirt1 and FOXO1 expression than controls.

AKT and EGFR pathway suppression

Urolithin A also suppresses phosphorylated AKT and EGFR expression in glioblastoma cells.

Both pathways are highly relevant in glioblastoma.

• AKT supports survival, proliferation, and apoptosis resistance, especially in PTEN-deficient tumours

• EGFR is amplified or altered in a large proportion of glioblastomas and drives downstream MAPK and PI3K/AKT signalling

TNF-α-induced AKT phosphorylation was also reduced by Urolithin A.

That connects its antiproliferative effects with inflammatory tumour-microenvironment signalling.

No Urolithin-A-specific EGFRvIII dataset was identified.

That remains an important gap because EGFRvIII is one of the most aggressive clinically relevant EGFR alterations in glioblastoma.

Tumour microenvironment — VCAM-1, PD-L1, and monocyte adhesion

This is one of the most clinically interesting parts of the glioblastoma evidence base.

Glioblastoma is not only a tumour-cell problem.

It is also a profoundly immunosuppressive microenvironment problem.

Urolithin A reduced TNF-α-induced VCAM-1 expression in glioblastoma cells.

That matters because VCAM-1 helps drive monocyte adhesion and recruitment into tumour tissue, where those cells can become tumour-promoting macrophages.

Functional co-culture work showed that lower VCAM-1 translated into lower monocyte binding.

Urolithin A also reduced TNF-α-induced PD-L1 expression on glioblastoma cells.

That is important because PD-L1 is a major immune-evasion mechanism.

Reducing PD-L1 expression could, in theory, make tumour cells less able to exhaust infiltrating T cells and NK cells.

At this stage, that remains mechanistically interesting rather than clinically proven.

Still, taken together, the VCAM-1 and PD-L1 findings suggest that Urolithin A may act at two different microenvironment levels:

• less recruitment of tumour-supportive monocytes

• less checkpoint-style immune evasion on tumour cells

In vivo xenograft evidence

Urolithin A's anti-glioblastoma signal has been validated in two in vivo settings.

Sirt1-FOXO1 xenograft model

In an immunodeficient mouse xenograft, Urolithin A treatment reduced tumour volume and weight compared with vehicle controls.

Tumour tissue also showed higher Sirt1 and FOXO1 expression, matching the in vitro mechanism.

ALTS1C1 syngeneic model

In a syngeneic glioblastoma model using ALTS1C1 cells, Urolithin A also reduced tumour growth.

This is especially useful because a syngeneic model preserves immune interactions.

That makes the PD-L1, VCAM-1, and monocyte-adhesion findings more meaningful than they would be in a fully immune-deficient system.

The blood-brain-barrier-integrity dimension

There is also a second CNS angle worth noting.

Outside direct tumour studies, Urolithin A has shown the ability to protect blood-brain-barrier integrity in a traumatic-brain-injury model.

Reported findings included:

• less brain oedema

• less Evans Blue leakage

• preservation of ZO-1 and occludin

• suppression of PI3K/AKT/mTOR and AKT/IKK/NF-κB signalling in CNS tissue

This is not a glioblastoma model.

So it cannot be presented as direct anti-glioblastoma proof.

What it does show is that Urolithin A has real CNS-active biology at relatively low doses beyond simple tumour-cell toxicity.

That makes the brain-tumour story more plausible, not more proven.

Temozolomide — the obvious gap

Temozolomide remains the core chemotherapy backbone in glioblastoma.

A major gap in the current Urolithin-A evidence base is that no published study has directly tested Urolithin A plus temozolomide in glioblastoma models.

That gap matters because there is a real mechanistic rationale for the combination.

Urolithin A suppresses AKT/mTOR signalling, and that pathway is linked to glioblastoma survival and treatment resistance.

Autophagy-related biology may also matter in temozolomide resistance.

Even so, as of April 2026, the combination has not been directly tested in published glioblastoma work.

That makes it one of the clearest next-step experiments the field still needs.

What remains unknown

Several major limits still define this page.

• no clinical trials in glioblastoma patients

• no published data on Urolithin A plus temozolomide

• no published data on Urolithin A plus radiotherapy in glioblastoma

• no clear answer yet on EGFRvIII-specific glioblastoma response

• no proof that PD-L1 reduction in vitro translates into meaningful in vivo immune control in patients

• no long-term neurological safety data in patients with active glioblastoma

• no clear pharmacokinetic proof yet that standard oral dosing reaches the same effective tissue concentrations used in glioblastoma cell-line work

Bottom line

Glioblastoma is one of the more credible non-gastrointestinal cancer settings for Urolithin A.

That rests on several strengths:

• confirmed blood-brain-barrier penetration

• repeated antiproliferative findings across multiple glioblastoma lines

• a functionally validated Sirt1-FOXO1 mechanism

• AKT and EGFR pathway suppression

• tumour-microenvironment effects involving VCAM-1 and PD-L1

• two separate in vivo growth-inhibition models

The evidence is still entirely preclinical.

Even so, the glioblastoma story is stronger than it first appears and deserves serious attention.

References

Inhibitory effects of Urolithins on glioblastoma
https://pmc.ncbi.nlm.nih.gov/articles/PMC10708538/

Inhibition of glioblastoma progression by Urolithin A in vitro and in vivo by regulating the Sirt1-FOXO1 axis via ERK/AKT signalling pathways
https://pubmed.ncbi.nlm.nih.gov/34818027/

AACR abstract on Urolithin A across three genetically diverse glioblastoma cell lines
https://aacrjournals.org/cancerres/article/80/16_Supplement/2972/642502/

Urolithin A alleviates blood-brain-barrier disruption following traumatic brain injury in mice
https://pmc.ncbi.nlm.nih.gov/articles/PMC8848621/

Urolithin A research overview and oncology applications
https://pmc.ncbi.nlm.nih.gov/articles/PMC12188533/

Urolithins as a possible alternative in brain ageing and neurodegeneration research
https://pmc.ncbi.nlm.nih.gov/articles/PMC10534540/